Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METEOR
  • Sponsors Exelixis

    • Most Recent Events

    • 04 Jun 2024 Results (n=43) assessing Cabozantinib outcomes in the first to third line setting for mRCC using METEOR trial as the comparator for response rates and progression-free survival presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Results analyzed tumor samples from this METEOR trial to assess whether AXL expression predicts improved clinical outcomes with cabozantinib relative to everolimus patients with metastatic clear cell Renal Cell Carcinoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jan 2022 Results of post hoc sub-analysis of METEOR study, assessing outcomes for patients recruited from European and non-European countries, published in the Acta Oncologica
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top